Jump to content
Fantasy Football - Footballguys Forums

Recommended Posts

So what was today all about?  Things go way up yesterday then way down today.

I know some of you had been talking about institutional rebalancing which could bring equities down.  So a combo of that and covid news?

My Roth is now about 80% invested and will be 100% invested as soon as some funds settle.  I have 6 dividend stocks I am just going to ride and leave alone.  DFS, PFE, PM, JPM, XOM, T (todem special).  Not a huge amount of money since I just opened a Roth this year.

My brokerage is about 40% deployed split up between about 10 different things.  CYDY my only green of course today🥰

Rooting for green.  Could use a green day.

Link to post
Share on other sites
  • Replies 57k
  • Created
  • Last Reply

Top Posters In This Topic

  • fantasycurse42

    3538

  • BassNBrew

    2941

  • stbugs

    2933

  • cosjobs

    1947

Top Posters In This Topic

Popular Posts

I will make a wager. If this stock hits $420.69 before this earnings call on March 31st, I will pass out 100 FBG subscriptions to the gents in the stock thread.

sponks

Good morning.   Value/dividend picks today for those seeking current income, and some long term moderate growth. These stocks are highly defensive.    MDU EXC VZ GIS

1 minute ago, BassNBrew said:

Going to be some really pissed people if it's a takeover before this really takes off.  Hopefully it's the former

Damn right.  Every day without a takeover gets the company one day closer to a COVID-19 approval.  They need to do everything possible to avoid BP announcing their interest in buying the CYDY before an approval.  With an approval, the price of poker goes up exorbitantly for big pharma.  

  • Like 3
Link to post
Share on other sites
Just now, ghostguy123 said:

So what was today all about?  Things go way up yesterday then way down today.

I know some of you had been talking about institutional rebalancing which could bring equities down.  So a combo of that and covid news?

My Roth is now about 80% invested and will be 100% invested as soon as some funds settle.  I have 6 dividend stocks I am just going to ride and leave alone.  DFS, PFE, PM, JPM, XOM, T (todem special).  Not a huge amount of money since I just opened a Roth this year.

My brokerage is about 40% deployed split up between about 10 different things.  CYDY my only green of course today🥰

Rooting for green.  Could use a green day.

I have a little JPM I stashed for long term, need to add some T.  PPL got close to $25 today but didn't quite make it.  I already have a little but at $25 I'd take another block.

Link to post
Share on other sites
1 minute ago, stbugs said:

@cosjobs FSLY ended positive a smidge.

yep. I still have tomorrow. But somehow winning / losing a couple hundred on that doesn't bother me when I'm making 4-5 figures a day on ChetYDY.

Also, I seldom directly tell someone to buy or not buy something, but Wind Cries Mary has had such a tough run, I wanted to prevent him from getting another gut punch.

Link to post
Share on other sites
48 minutes ago, ghostguy123 said:

So what was today all about?  Things go way up yesterday then way down today.

I know some of you had been talking about institutional rebalancing which could bring equities down.  So a combo of that and covid news?

 

As always, the answer isn't as obvious and usually a combination of those factors and others. A lot of the re-balancing happens later in the day so that is why you'll see some late day sell-offs. Like that is what I'd say the 50 bps sell-off in the SPY was towards the end of the day and recouped 25 bps of that in AH trading. But could have some rebalancing throughout the day. Folks could be getting ahead of this selling. Coupled with negative headlines out. Sentiment appears pretty meh. Where is the incremental buyer to take this higher? Folks point to HFs and money on the side but no indication they're going to chase. Likewise, put/calls and retail folks appear pretty fully invested. Pensions and the like aren't likely to be buyers given the rebalancing. Buybacks seemed to be driving the markets the past few years and I'd be those are on pause although some smart firms that can get away with it are likely doing them. Stonks only go up when folks have money to invest. 

Link to post
Share on other sites
9 minutes ago, BassNBrew said:

Congrats. Please share your buy and hold strategy that produced a 4x as the Rest of us want To tail it

I post most of my large plays here and many of the small ones. I'm mostly contrarian, except for CYDY. But most of the money I plowed into CYDY came from TVIX.

ETA - the only thing I've held for three months is CYDY, CEF and my Johnson. But pretty sure you are already a short term guy. Oh and a couple semi-worthless penny stock: MDIT 15,000 shares (worth Maybe $400) and 20,000 shares CBLLF (worth about $40)

Edited by cosjobs
Link to post
Share on other sites
Just now, cosjobs said:

yep. I still have tomorrow. But somehow winning / losing a couple hundred on that doesn't bother me when I'm making 4-5 figures a day on ChetYDY.

Also, I seldom directly tell someone to buy or not buy something, but Wind Cries Mary has had such a tough run, I wanted to prevent him from getting another gut punch.

I was surprised it ended green, but IMHO that shows the strength it may have now. CYDY has been fun. It’s now my second largest gain dollar wise, still way behind AMZN but better than everything else including some great buys.

Cumulus Cries Mary has. He’s a bat signal to everyone who owns SE to be on the lookout for a rumor that they are cooking their books. If he owns SE, it’s most likely true.

  • Laughing 1
Link to post
Share on other sites
1 minute ago, stbugs said:

I was surprised it ended green, but IMHO that shows the strength it may have now. CYDY has been fun. It’s now my second largest gain dollar wise, still way behind AMZN but better than everything else including some great buys.

Cumulus Cries Mary has. He’s a bat signal to everyone who owns SE to be on the lookout for a rumor that they are cooking their books. If he owns SE, it’s most likely true.

Yeah, I was late to the SE party, but happily made 10-15% on a fairly large position, but that late fade Tue and my spidey sense telling me volatility was coming, I dumped it all Tuesday.

Tbh, my spidey sense is often over reactive to volatility. That or the Fed hates me/volatility no matter the price tag. They've been tough opponents.

Link to post
Share on other sites
1 minute ago, cosjobs said:

I post most of my large plays here and many of the small ones. I'm mostly contrarian, except for CYDY. But most of the money I plowed into CYDY came from TVIX.

Congrats. I don’t think your type of trades are wise for most of us. I have one account that is 100% of my retirement fund. 15% is my max allocation in one place. I have to fight and claw to make a gain on the market. I have no problem taking gains to move into something else. Up about 40% this year without any huge exposure 

Link to post
Share on other sites
4 minutes ago, cosjobs said:

Yeah, I was late to the SE party, but happily made 10-15% on a fairly large position, but that late fade Tue and my spidey sense telling me volatility was coming, I dumped it all Tuesday.

Tbh, my spidey sense is often over reactive to volatility. That or the Fed hates me/volatility no matter the price tag. They've been tough opponents.

So basically you did what I’ve been doing

Link to post
Share on other sites
2 minutes ago, BassNBrew said:

Congrats. I don’t think your type of trades are wise for most of us. I have one account that is 100% of my retirement fund. 15% is my max allocation in one place. I have to fight and claw to make a gain on the market. I have no problem taking gains to move into something else. Up about 40% this year without any huge exposure 

That's a huge number. I guess I was lucky/prescient in load up on TVIX when I started really tracking COVID in Feb/Mar and then tailed Chet with a lot of the proceeds. 

Link to post
Share on other sites
3 minutes ago, BassNBrew said:

So basically you did what I’ve been doing

Similar methodology, but I'm a bear and you're a bull. We've both had opportunities to shine the last few months.

Link to post
Share on other sites
Just now, cosjobs said:

That's a huge number. I guess I was lucky/prescient in load up on TVIX when I started really tracking COVID in Feb/Mar and then tailed Chet with a lot of the proceeds. 

Happy for you. That’s life changing success. 

Link to post
Share on other sites
2 hours ago, Slapdash said:

Sounds like an upgrade to me :coffee: 

We really need gun duels to be a legal thing...

 

2 hours ago, BassNBrew said:

Nope.  Sand went to Clemson, lives in Arkansas.  It was a joke about his kids having to go to Bama rather than Clemson (cheaper tuition) because he bought into Disney to high.  I'm trying to prevent him from having to live with that.

Some things are way beyond monetary concern.  Not having to listen to a kid say "Roll Tide" for the rest of my life is worth $$$.

  • Like 2
  • Love 1
  • Laughing 4
Link to post
Share on other sites
Just now, Sand said:

We really need gun duels to be a legal thing...

 

Some things are way beyond monetary concern.  Not having to listen to a kid say "Roll Tide" for the rest of my life is worth $$$.

That’s why I’m trying to get you in Disney in the 90s

  • Thanks 1
Link to post
Share on other sites

Reminder that bank stress tests results are after the close tomorrow. Could be some volatility if GS Research is correct on this, but who knows how politics will play into the Fed's decision:

Over the past three months, the options market has priced in 40% lower average 2021 dividends across large cap banks, and consensus is forecasting 11% lower dividends for the top 7 banks relative to the beginning of the year, which we believe is related to investor concerns for higher capital requirements in 2020 CCAR that could force banks to cut dividends (Exhibit 8, Exhibit 10). In our view, bank capital levels remain sufficient, especially in light of higher near-term earnings guidance, and should reassure investors that, aside from at WFC, bank dividends are likely not at risk.

  • Like 2
Link to post
Share on other sites
9 minutes ago, BassNBrew said:

Happy for you. That’s life changing success. 

Thanks and you are right about life-changing. I "retired" late last year and my wife had to retire early this year and we lost her insurance ###. So it was very fortunate time to hit a homerun. 

  • Like 5
  • Love 1
Link to post
Share on other sites
8 minutes ago, Slapdash said:

Reminder that bank stress tests results are after the close tomorrow. Could be some volatility if GS Research is correct on this, but who knows how politics will play into the Fed's decision:

Over the past three months, the options market has priced in 40% lower average 2021 dividends across large cap banks, and consensus is forecasting 11% lower dividends for the top 7 banks relative to the beginning of the year, which we believe is related to investor concerns for higher capital requirements in 2020 CCAR that could force banks to cut dividends (Exhibit 8, Exhibit 10). In our view, bank capital levels remain sufficient, especially in light of higher near-term earnings guidance, and should reassure investors that, aside from at WFC, bank dividends are likely not at risk.

If the results aren't great, I expect 2800ish S&P Friday

Link to post
Share on other sites

CytoDyn Inc (OTCMKTS:CYDY) Makes Waves in the NASH Space
By James Hudson - June 24, 2020
SHAREFacebook Twitter  

 
CytoDyn Inc (OTCMKTS:CYDY) just announced initiation of the Company’s Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2 trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.

As previously reported, the Company’s preclinical study demonstrated strong positive data highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to nonalcoholic steatohepatitis (NASH). These data, along with previous findings showing that leronlimab inhibits liver fibrosis, suggests the potential of leronlimab to control both the early and late stages of NASH.

CytoDyn Inc (OTCMKTS:CYDY) promulgates itself as a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.

Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease.


 
CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

According to company materials, “CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.”

 As noted above, CYDY just announced initiation of the Company’s Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Recent action has seen 46% tacked on to share pricing for the name in the past week. Furthermore, the stock has seen a growing influx of trading interest, with the stock’s recent average trading volume running 10% over what the stock has registered over the longer term.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are excited to continue to advance the evaluation of leronlimab for a potential therapeutic benefit for NASH, a disease with an increasing prevalence in the U.S.  Our strategic plan to execute a multi-pathway approach to exploring all potential benefits of leronlimab has led to cancer, COVID-19 and now potentially NASH, along with other immunologic indications.”

Earning a current market cap value of $2.3B, CYDY has a significant war chest ($7.1M) of cash on the books, which compares with about $41M in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. We will update the story again soon as further details emerge.

 

NOTE: New clinical trials showing effectiveness in curing old age and death.

  • Laughing 3
Link to post
Share on other sites
4 minutes ago, cosjobs said:

CytoDyn Inc (OTCMKTS:CYDY) Makes Waves in the NASH Space
By James Hudson - June 24, 2020
SHAREFacebook Twitter  

 
CytoDyn Inc (OTCMKTS:CYDY) just announced initiation of the Company’s Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2 trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.

As previously reported, the Company’s preclinical study demonstrated strong positive data highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to nonalcoholic steatohepatitis (NASH). These data, along with previous findings showing that leronlimab inhibits liver fibrosis, suggests the potential of leronlimab to control both the early and late stages of NASH.

CytoDyn Inc (OTCMKTS:CYDY) promulgates itself as a late-stage biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection.

Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease.


 
CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

According to company materials, “CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.”

 As noted above, CYDY just announced initiation of the Company’s Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Recent action has seen 46% tacked on to share pricing for the name in the past week. Furthermore, the stock has seen a growing influx of trading interest, with the stock’s recent average trading volume running 10% over what the stock has registered over the longer term.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are excited to continue to advance the evaluation of leronlimab for a potential therapeutic benefit for NASH, a disease with an increasing prevalence in the U.S.  Our strategic plan to execute a multi-pathway approach to exploring all potential benefits of leronlimab has led to cancer, COVID-19 and now potentially NASH, along with other immunologic indications.”

Earning a current market cap value of $2.3B, CYDY has a significant war chest ($7.1M) of cash on the books, which compares with about $41M in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. We will update the story again soon as further details emerge.

 

NOTE: New clinical trials showing effectiveness in curing old age and death.

What’s left other than penis enhancement 

  • Laughing 8
Link to post
Share on other sites

I do have a small issue with the current run up since last Friday. I’ve been celebrating after the big days and have been hungover all week. I have a monthly CG golf tourney tomorrow, gonna be one hungover SOB as I can’t change routine now :banned: 

  • Like 1
  • Laughing 1
Link to post
Share on other sites
1 hour ago, sporthenry said:

As always, the answer isn't as obvious and usually a combination of those factors and others. A lot of the re-balancing happens later in the day so that is why you'll see some late day sell-offs. Like that is what I'd say the 50 bps sell-off in the SPY was towards the end of the day and recouped 25 bps of that in AH trading. But could have some rebalancing throughout the day. Folks could be getting ahead of this selling. Coupled with negative headlines out. Sentiment appears pretty meh. Where is the incremental buyer to take this higher? Folks point to HFs and money on the side but no indication they're going to chase. Likewise, put/calls and retail folks appear pretty fully invested. Pensions and the like aren't likely to be buyers given the rebalancing. Buybacks seemed to be driving the markets the past few years and I'd be those are on pause although some smart firms that can get away with it are likely doing them. Stonks only go up when folks have money to invest. 

Oh and CNBC now saying some of it is Biden. https://www.cnbc.com/2020/06/24/bidens-big-lead-in-the-polls-could-be-partly-behind-markets-drop-and-may-lead-to-more-weakness.html

The problem with this market which is pure sentiment and technical driven, it doesn't take much for it to turnover. Sentiment is a fickle thing. Everyone seems to be buying, figuring the guy behind them will buy and push the stock up. Once that circular reference (i.e. House of Cards) stops spinning, things go down. I'm not saying we're going to 2,700 but I think you'll drive yourself crazy looking to make sense of every move. I've honestly been trying to follow more technical stuff (like gamma, option expiry, pension fund rebalancing) since fundamentals don't matter and I'm looking to avoid massive moves one way or the other. But seems pretty irrational for the market to start freaking out over Biden compared to one or two weeks ago.

Link to post
Share on other sites
55 minutes ago, cosjobs said:

If the results aren't great, I expect 2800ish S&P Friday

Honestly I'd look at that as a good thing for me personally who is still heavy on cash.  Got a good chunk of 2020's 401K funds sitting in the money market that only arrived in the past 5-6 weeks to the account.

Edited by Shula-holic
Link to post
Share on other sites
3 minutes ago, Shula-holic said:

Honestly I'd look at that as a good thing for me personally who is still heavy on cash.  Got a good chunk of 2020's 401K funds sitting in the money market that only arrived in the past 5-6 weeks to the account.

That's where we were five weeks ago. Why is anyone taking the possibility off the table now? 

Link to post
Share on other sites
2 hours ago, ghostguy123 said:

So for those of you with any sort of significant amount of CYDY and low cost basis, did you add any more today?  Do you plan to add more?

No more for me, would add too much more incremental risk...by not taking any off the table that’s big enough for me

Link to post
Share on other sites
3 hours ago, ghostguy123 said:

So for those of you with any sort of significant amount of CYDY and low cost basis, did you add any more today?  Do you plan to add more?

I really want to but haven't pulled the trigger. Likely will just stick with the shares I have unless a wave of FOMO crashes over me. 

  • Like 1
Link to post
Share on other sites
2 minutes ago, eaganwildcats said:
3 hours ago, ghostguy123 said:

So for those of you with any sort of significant amount of CYDY and low cost basis, did you add any more today?  Do you plan to add more?

I really want to but haven't pulled the trigger. Likely will just stick with the shares I have unless a wave of FOMO crashes over me. 

Agreed.  I have 3k @ an .88 average.  Would have to outlay more then I’m comfortable with to significantly increase my position at this time   Just gonna stick and hold.   $30 or bust!   

 

Link to post
Share on other sites
3 hours ago, ghostguy123 said:

So for those of you with any sort of significant amount of CYDY and low cost basis, did you add any more today?  Do you plan to add more?

I have essentially doubled my cost basis in the past week. Definitely some FOMO. But I'll probably have a very tight stop loss for my recent shares. Honestly, probably something like 5-10%. Just as this could go parabolic, could easily see it drop back to $3. 

  • Like 1
Link to post
Share on other sites

Question:

I have a stock exchange program that I participate in my for my company. I currently have about 550 shares in my company and will be purchasing more (at 15% off) at the end of June. I have accumulated the first 550 shares over the last ~5 plus years and most of them are owned for more than 1 year.

In order to further diversify into some other stocks, I am trying to understand the tax implications - what sort of tax hit I would be taking IF I sold the shares I purchase next week to then purchase additional stocks?

Example: If the stock is $100.00, I will be able to purchase for $85.00. Let's say I am able to buy 10 shares for $850.00 and then dump back into the market for $1,000.00. For my taxes next year, would I get taxed at 15% or 35% AND would that be on the $150.00 profit or would there be any other tax hit I need to account for?

Another question - If I were to sell the 550 stocks mentioned above and cash out on my earnings, would I be taxed at 15% for each of them or do I have to have had each share opened for at least a year? Not sure if/when I'd get taxed at 35% vs. 15%.

In any case, considering this option in early July to make some additional purchases, but want to make sure I understand how much in taxes I will have to account for in 2021.

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...